Tiotropium: what came after the UPLIFT study

Bibliography

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease, 2010. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html [Last accessed 28 October 2011]
   Google Scholar
• La gestione Clinica Integrata Della BPCO. Burson-Marsteller; Milano: 2011
   Google Scholar
• Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63-S
   PubMed Web of Science ®Google Scholar
• Santus P, Di Marco F. Safety and pharmacological profile of tiotropium bromide. Expert Opin Drug Saf 2009;8:387-95
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Zierenberg B, Eicher J, Dunne S, Boehringer Ingelheim nebulizer BINEB: a new approach to inhalation therapy. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery V. Interpharm Press; Buffalo Grove: 1996
   Google Scholar
• Dalby R, Spallek M, Voshaar T. Review of the development of respimat soft mist inhaler. Int J Pharm 2004;28:1-9
   Google Scholar
• Dal Negro RW, Bonadiman L, Micheletto C, Changes of clinical outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18 mcg od for twenty-four months. Pulm Pharmacol Ther 2011;24:373-6
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S, Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Ten Hacken NH. Randomised controlled trial: uplifting results of tiotropium in moderate COPD (GOLD stage 2). Evid Based Med 2010;15:44-5
   PubMedGoogle Scholar
• Anzueto A, Miravitlles M. Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther Adv Respir Dis 2009;3:103-11
   PubMedGoogle Scholar
• Halpin D, Menjoge S, Viel K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J 2009;18:106-13
   PubMedGoogle Scholar
• Cooper CB, Anzueto A, Decramer M, Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis 2011;6:269-75
   PubMed Web of Science ®Google Scholar
• Tonnel AB, Perez T, Grosbois JM, Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:301-10
   PubMedGoogle Scholar
• Kaplan A. Effect of tiotropium on quality of life in COPD: a systematic review. Prim Care Respir J 2010;19:315-25
   PubMedGoogle Scholar
• Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011;56:477-87
   PubMed Web of Science ®Google Scholar
• Puente-Maestu L, De Miguel J. Family increases: UPLIFT first maintenance subgroup analysis. Eur Respir J 2010;36:10-11
   PubMedGoogle Scholar
• Troosters T, Celli B, Lystig T, Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65-73
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Kesten S, Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010;35:287-94
   PubMed Web of Science ®Google Scholar
• Morice AH, Celli B, Kesten S, COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010;104:1659-67
   PubMed Web of Science ®Google Scholar
• Bedard ME, Brouillard C, Pepin V, Tiotropium improves walking endurance in chronic obstructive pulmonary disease. Eur Respir J 2011; published online 23 June 2011, doi: 10.1183/09031936.00059511
   PubMedGoogle Scholar
• Voshaar T, Lapidus R, Maleki-Yazdi R, A randomized study of tiotropium Respimat® Soft Mist inhaler vs ipratropium pMDI in COPD. Respir Med 2008;102:32-41
   PubMed Web of Science ®Google Scholar
• Bateman E, Singh D, Smith D, Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010;5:197-208
   PubMedGoogle Scholar
• Bateman ED, Tashkin D, Siafakas N, A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010;104:1460-72
   PubMed Web of Science ®Google Scholar
• Van Noord JA, Cornelissen PJ, Aumann JL, The efficacy of tiotropium administered via respimat soft mist inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9
   PubMed Web of Science ®Google Scholar
• Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 microg via Respimat and 18 microg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 2010;104:228-36
   PubMed Web of Science ®Google Scholar
• Short PM, Williamson PA, Elder DH, The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest 2011; published online 28 July 2011; doi:10.1378/chest.11-0038
   Google Scholar
• Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;16:CD008532
   Google Scholar
• Bateman ED, van Dyk M, Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulm Pharmacol Ther 2008;21:20-5
   PubMedGoogle Scholar
• Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med 2010;10:50
   PubMedGoogle Scholar
• Vogelmeier C, Hederer B, Glaab T. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103
   PubMed Web of Science ®Google Scholar
• Tashkin DP. Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis 2010;5:41-53
   PubMedGoogle Scholar
• Zhang J, Deng L, Xiong X, Effect of tiotropium bromide on expression of CD(8) (+)CD (25) (+)FoxP (3) (+) regulatory T cells in patients with stable chronic obstructive pulmonary disease. J Huazhong Univ Sci Technolog Med Sci 2011;31:463-8
   PubMedGoogle Scholar
• Santus P, Centanni S, Verga M, Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med 2006;100:1277-81
   PubMed Web of Science ®Google Scholar
• Gelb AF, Taylor CF, Cassino C, Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther 2009;22:237-42
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Makita H, Nasuhara Y. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax 2009;64:332-8
   PubMed Web of Science ®Google Scholar
• Ram FS. Tiotropium mist inhaler for COPD increases risk of mortality compared with placebo. Evid Based Med 2011;16:189-90
   PubMedGoogle Scholar
• Singh S, Loke YK, Enright PL, Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215
   PubMed Web of Science ®Google Scholar